Grifols SA, Barcelona (GRFS) Upgraded by Zacks Investment Research to “Hold”
Zacks Investment Research upgraded shares of Grifols SA, Barcelona (NASDAQ:GRFS) from a sell rating to a hold rating in a research note released on Thursday morning.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Other equities research analysts have also issued research reports about the stock. BidaskClub raised shares of Grifols SA, Barcelona from a strong sell rating to a sell rating in a report on Wednesday, December 20th. UBS Group lowered shares of Grifols SA, Barcelona from an outperform rating to a market perform rating in a research note on Friday, November 24th. Finally, Citigroup assumed coverage on shares of Grifols SA, Barcelona in a research note on Tuesday, October 31st. They set a buy rating on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $24.00.
Shares of Grifols SA, Barcelona (NASDAQ GRFS) traded up $0.27 during trading on Thursday, reaching $24.25. 446,284 shares of the company’s stock were exchanged, compared to its average volume of 753,320. The company has a market cap of $6,270.00, a price-to-earnings ratio of 25.78, a PEG ratio of 1.60 and a beta of 1.03. Grifols SA, Barcelona has a 1-year low of $16.37 and a 1-year high of $24.37. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.39 and a current ratio of 3.17.
Large investors have recently bought and sold shares of the stock. Lenox Wealth Management Inc. boosted its stake in Grifols SA, Barcelona by 8,372.9% during the third quarter. Lenox Wealth Management Inc. now owns 5,931 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,861 shares in the last quarter. First Republic Investment Management Inc. bought a new stake in Grifols SA, Barcelona during the third quarter worth about $203,000. Advisory Services Network LLC boosted its stake in Grifols SA, Barcelona by 26.2% during the second quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 1,987 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Grifols SA, Barcelona during the second quarter worth about $223,000. Finally, Stevens Capital Management LP bought a new stake in Grifols SA, Barcelona during the second quarter worth about $236,000. 22.50% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Grifols SA, Barcelona (GRFS) Upgraded by Zacks Investment Research to “Hold”” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/grifols-sa-barcelona-grfs-upgraded-by-zacks-investment-research-to-hold/1798834.html.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with Analyst Ratings Network's FREE daily email newsletter.